Fungi are the leading cause of insect disease, contributing to the decline of wild and 25 managed populations 1,2 . For ecologically and economically critical species, such as the 26 European honey bee (Apis mellifera), the presence and prevalence of fungal pathogens can 27 have far reaching consequences, endangering other species and threatening food 28 security 3,4,5 . Our ability to address fungal epidemics and opportunistic infections is 29 currently hampered by the limited number of antifungal therapies 6,7 . Novel antifungal 30 treatments are frequently of bacterial origin and produced by defensive symbionts 31 (bacteria that associate with an animal/plant host and protect against natural enemies 89 . 32 Here we examined the capacity of a honey bee-associated bacterium, Bombella apis, to 33 suppress the growth of fungal pathogens and ultimately protect bee brood (larvae and 34 pupae) from infection. Our results showed that strains of B. apis inhibit the growth of two 35 insect fungal pathogens, Beauveria bassiana and Aspergillus flavus, in vitro. This phenotype 36 was recapitulated in vivo; bee brood supplemented with B. apis were significantly less likely 37 to be infected by A. flavus. Additionally, the presence of B. apis reduced sporulation of A. 38 flavus in the few bees that were infected. Analyses of biosynthetic gene clusters across B. 39 apis strains suggest antifungal production via a Type I polyketide synthase. Secreted 40 metabolites from B. apis alone were sufficient to suppress fungal growth, supporting this 41 hypothesis. Together, these data suggest that B. apis protects bee brood from fungal 42 infection by the secretion of an antifungal metabolite. On the basis of this discovery, new 43 antifungal treatments could be developed to mitigate honey bee colony losses, and, in the 44 future, could address fungal epidemics in other species. 45 Emerging fungal pathogens pose major threats to animal and plant populations 2 . Among 46 insects, fungal pathogens are currently the most common causal agents of disease, and 47 historically have plagued insect hosts for over 300 million years 1,10 . In recent years, fungal 48 pathogens have contributed to the unprecedented population decline of honey bees, causing 49 opportunistic infections in already stressed colonies 3,4 . Within the colony, the most susceptible 50
co-cultured with B. apis. The number of spores produced by both B. bassiana and A. flavus, was 80 reduced by an order of magnitude on average (Fig 1c) , showing that B. apis can suppress growth 81 of both pathogens. 82 To test if B. apis is capable of preventing fungal infections in vivo, we collected larvae 83 from our apiary and reared them on a diet supplemented with either B. apis or a sterile media 84 control. Once reared to pupae, the cohort was inoculated with A. flavus or a sterile media control 85 and presence of infection was scored until adulthood (Fig 2a) . Pupae that were supplemented 86 with B. apis as larvae were significantly more likely to resist fungal infection ( < = 14.8, df = 1, 87 p < 0.001), with 66% of the cohort surviving to adulthood with no signs of infection (Fig 2b,c) . 88 In sharp contrast, without B. apis, no pupae survived to adulthood (Fig 2b, d) . Interestingly, in 89 the 34% of B. apis-supplemented pupae that succumbed to fungal infection, the number of spores 90 produced was 68% on average (Fig 2e; t = 2.9116, df = 8.4595 , p = 0.02). Taken together, these 91 results suggest that the presence of B. apis increases the host's likelihood of survival under 92 fungal challenge, while decreasing the pathogen's spore load and potential to spread infection to 93 new hosts. 94 To determine if B. apis produces antifungal metabolite(s), we incubated fungi in spent it is likely that B. apis inhibits fungi via secretion of an antifungal secondary metabolite(s). We 102 used antiSMASH 26 to annotate secondary metabolite gene clusters in the genomes of all B. apis 103 strains used in this study and found that all strains have a conserved type 1 polyketide synthase 104 (T1PKS) region. Type 1 polyketide synthases are common among host-associated microbes and 105 produce macrolides which often have antifungal activity 8, 27, 28, 29 . Additionally, all B. apis strains 106 contain an aryl polyene synthesis cluster. The commonly used antifungals amphotericin, nystatin 107 and pimaricin are all polyenes, suggesting that this gene cluster may also contribute to the 108 production of antifungal compound(s). Further functional characterization of these gene clusters 109 will help elucidate whether they play a role in the antifungal phenotype of B. apis. Considering 110 the antifungal activity of B. apis secreted metabolites in vitro and our genomic predictions, it is 111 likely that B. apis synthesizes and secretes a metabolite capable of inhibiting fungi.
112
Our results provide evidence that a honey bee-associated bacterium, B. apis, is capable of downloaded from GenBank (see Table 1 .114, df = 2, p = 0.19; B8: t = 11.147, df 248 = 3, p = 0.006; C6: t = 10.121, df = 2.7, p = 0.011; SME1: t = 12.352, df = 2, p = 0.025) and A. 249 flavus (A29: t = 2.8807, df = 2, p = 0.40; B8: t = 2.9033, df =2, p = 0.39; C6: t = 3.0137, df = 2, 250 p = 0.37; SME1: t = 3.1679, df = 2, p = 0.34), depending on B. apis strain identity. Isolates and culturing 284 All bacterial strains of B. apis and were obtained by sampling either nectar or larvae ( B. apis strains were grown to their maximal OD, and all strains were normalized to the 301 lowest OD value by diluting in fresh media. 10 @ spores of each fungal isolate were incubated 302 in 100 µl of density-normalized B. apis culture or 100 µl of fresh media. Fungal growth was 303 monitored daily and once controls showed sporulation, spore counts were quantified for each 304 well via hemocytometer.
